Scottish Medicines Consortium

Adalimumab (Humira^{Ò}) (No. 81/03)

Abbott Laboratories

Summary of Recommendation

8 December, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: Following a full submission.

Adalimumab (Humira®) is accepted for restricted use within NHS Scotland for the treatment of rheumatoid arthritis (RA).

It should be initiated only by specialist physicians experienced in the diagnosis and treatment of RA, and used in accordance with British Society Rheumatology (BSR) guidelines for prescribing TNF-α blockers in adults [which have been endorsed by the National Institute of Clinical Excellence (NICE) and QIS]. The BSR have established a Biologics Registry and details of patients treated with TNF-antagonists including adalimumab should be entered into this database. Adalimumab is the third TNF-antagonist licensed for the treatment rheumatoid arthritis (RA).

Professor David H Lawson
Chairman

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6997 Fax 0141 248 3778
E-mail jmitchell@htbs.org.uk

Chairman Professor David Lawson